Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138354 · Präparat HOS-098186
In the safety pool for CUPID studies (A, B, and C) no increase was observed in the overall incidence of infections with dupilumab compared to placebo. In the safety pool, serious infections were observed in 0.5% of patients treated with dupilumab and 0.5% of patients treated with placebo. No serious infections were observed in children treated with dupilumab in the PKM16982 study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage a5dd26a521f4ae63005cb225c66014cb6f920cb01bdf610984f78026f63698d9 · Zeichen 9125–9508 im Abschnitt